Advertisement

Cardiotoxicity Associated with Radiation for Breast Cancer

  • Kara Lynne LeonardEmail author
  • David E. Wazer
Chapter

Abstract

Women treated with radiotherapy (RT) for breast cancer may receive substantial radiation exposure to the heart, which may leave them at risk for increased risk of serious cardiac injury. Historically, women who received radiation therapy as part of their treatment for breast cancer were more likely to die of non-breast cancer-related causes than women who did not receive RT. More contemporary studies, however, suggest that with modern radiation planning techniques, cardiac dose from breast cancer irradiation is minimized in the average patient. Despite this, women undergoing contemporary RT for breast cancer may be at risk for cardiotoxicity as a result of higher than average cardiac dose due to variations in individual anatomy or comprehensive nodal treatment volumes. Moreover, individual risk factors such as comorbid cardiac illness, age, and administration of systemic therapy impact cardiac risk. Strategies to reduce cardiac dose, including deep inspiration breath hold, prone positioning, partial breast irradiation, and proton therapy should be considered, particularly in women at high risk for cardiotoxicity. Based on available data, most current protocols recommend limiting mean cardiac dose and the dose to 5% and 10% of the cardiac volume.

Keywords

Breast cancer RT Cardiac Cardiotoxicity Mean heart dose 

References

  1. 1.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effect of RT after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effect of RT after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRefGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of RT for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70.CrossRefGoogle Scholar
  4. 4.
    American Cancer Society: https://www.cancer.org. Global cancer facts and figures. 3rd edition. 2012. Accessed May 29 2018.
  5. 5.
    Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.CrossRefGoogle Scholar
  6. 6.
    Wu SP, Tam M, Vega RM, Perez CA, Gerber NK. Effect of breast irradiation on cardiac disease in women enrolled in BCIRG-001 at 10-year follow up. Int J Radiat Oncol Biol Phys. 2017;99:541–8.CrossRefGoogle Scholar
  7. 7.
    Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after RT for breast cancer. N Engl J Med. 2013;368:987–98.CrossRefGoogle Scholar
  8. 8.
    Taylor CW, Kirby AM. Cardiac side-effects from breast cancer RT. Clin Oncol. 2015;27:621–9.CrossRefGoogle Scholar
  9. 9.
    Taylor C, McGale P, Bronnum D, Correa C, Cutter D, Duane FK, et al. Cardiac structure injury after breast cancer RT: cross-sectional study with individual patient data. J Clin Oncol.  https://doi.org/10.1200/JCO.2017.77.6351. [Epub ahead of print]
  10. 10.
    van den Bogaard VAB, Ta BDP, van der Schaaf A, Bouma AB, Middag AMH, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with RT based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35:1171–8.CrossRefGoogle Scholar
  11. 11.
    Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after RT for early breast cancer: prospective cohort study of about 300,000 women in the US SEER cancer registries. Lancet Oncol. 2005;6:557–65.CrossRefGoogle Scholar
  12. 12.
    Vallis KA, Pintiline M, Chong N, Holowaty E, Douglas PS, Kirkbride P, Wielgasz A. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol. 2002;20:1036–42.CrossRefGoogle Scholar
  13. 13.
    Harris EER, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, Solin LJ. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24:4100–6.CrossRefGoogle Scholar
  14. 14.
    Hojris I, Overgaard M, Christensen JJ, Overgaard J, on behalf of the Danish Breast Cancer Cooperative Group. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without RT: analysis of DBCG 82b and 82c randomised trials. Lancet. 1999;354:1425–30.CrossRefGoogle Scholar
  15. 15.
    Early Breast Cancer Collaborative Group (EBCTCG). Overview of the randomized trials of RT in ductal carcinoma in situ of the breast. JNCI Monogr. 2000;41:162–77.Google Scholar
  16. 16.
    Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Gillespie EF, et al. Modern radiation therapy and cardiac outcomes in breast cancer. Int J Radiat Oncol Biol Phys. 2016;94:700–8.CrossRefGoogle Scholar
  17. 17.
    Rutter CE, Chagpar AB, Evans SB. Breast cancer laterality does not influence survival in a large modern cohort: implications for radiation-related cardiac mortality. Int J Radiat Oncol Biol Phys. 2014;90:329–34.CrossRefGoogle Scholar
  18. 18.
    Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortsmans P, Theuws JCM, et al. Cardiovascular disease in a population based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94:1061–72.CrossRefGoogle Scholar
  19. 19.
    Chang JS, Chen J, Weinberg VK, Fowble B, Sethi RA. Evaluation of heart dose for left-sided breast cancer patients over an 11-year period spanning the transition from 2-dimensional to 3-dimensional planning. Clin Breast Cancer. 2016;16:396–401.CrossRefGoogle Scholar
  20. 20.
    Lind PA, Pagnanelli R, Marks LB, et al. Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys. 2003;55:914–20.CrossRefGoogle Scholar
  21. 21.
    Zellars R, Bravo PE, Tryggestad E, Hopfer K, Myers L, Tahari A, et al. SPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordination: a randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2014;88:778–85.CrossRefGoogle Scholar
  22. 22.
    Lo Q, Hee L, Batumalai V, Allman C, MacDonald P, Delaney GP, et al. Subclinical cardiac dysfunction detected by strain imaging during breast irradiation with persistent changes 6 weeks after treatment. Int J Radiat Oncol Biol Phys. 2015;92:268–76.CrossRefGoogle Scholar
  23. 23.
    Lo Q, Hee L, Batumalai V, Allman C, MacDonald P, Lonergan D, et al. Strain imaging detects dose-dependent segmental cardiac dysfunction in the acute phase after breast irradiation. Int J Radiat Oncol Biol Phys. 2017;99:182–90.CrossRefGoogle Scholar
  24. 24.
    Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer RT: 1950s–1990s. Int J Radiat Oncol Biol Phys. 2007;69:1484–95.CrossRefGoogle Scholar
  25. 25.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86:860–6.CrossRefGoogle Scholar
  26. 26.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.CrossRefGoogle Scholar
  27. 27.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen EV, Budach V, Struikmans S, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317.CrossRefGoogle Scholar
  28. 28.
    Dess RT, Liss AL, Griffith KA, Marsh RB, Moran JM, Mayo C, et al. Ischemic cardiac events following treatment of the internal mammary nodal region using contemporary radiation planning techniques. Int J Radiat Oncol Biol Phys. 2019;99:1146–53.CrossRefGoogle Scholar
  29. 29.
    Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary RT for breast cancer. Circulation. 2017;135:1388–96.CrossRefGoogle Scholar
  30. 30.
    Hughes KS, Schnaper LA, Bellon J, Cirrincione C, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. J Clin Oncol. 2013;31:2382–7.CrossRefGoogle Scholar
  31. 31.
    Levis BE, Brinkley PF, Shaprio CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 2017;18:3445–56.CrossRefGoogle Scholar
  32. 32.
    Thavendiranathon P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, Lee DS. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol. 2016;34:2239–46.CrossRefGoogle Scholar
  33. 33.
    Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–305.CrossRefGoogle Scholar
  34. 34.
    Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, et al. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017;35:3942–4\8.CrossRefGoogle Scholar
  35. 35.
    Rehammar JC, Jensen MB, McGale P, Lorenzen EL, Taylor C, Darby SC, et al. Risk of heart disease in relation to RT and chemotherapy with anthracyclines among 19464 breast cancer patients in Denmark. RT Oncol. 2017;123:299–305.Google Scholar
  36. 36.
    Halyard MY, Pisansky TM, Cueck AC, Suman V, Pierce L, Solin L, et al. RT and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol. 2009;27:2638–44.CrossRefGoogle Scholar
  37. 37.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet. 2015;386:1341–52.CrossRefGoogle Scholar
  38. 38.
    Haque R, Shi J, Schottinger JE, Chung J, Avia C, Amundsen B, et al. Cardiovascular disease after aromatase inhibitor use. JAMA Oncol. 2016;2:1590–7.CrossRefGoogle Scholar
  39. 39.
    Shah C, Badiyan S, Berry S, Khan AJ, Goyal S, Schulte K, et al. Cardiac dose sparing and avoidance techniques in breast cancer RT. Radiother Oncol. 2014;112:9–16.CrossRefGoogle Scholar
  40. 40.
    Schubert LK, Gondi V, Sengbusch E, Westerly DC, Soisson ET, Paliwal BR, et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol. 2011;100:241–6.CrossRefGoogle Scholar
  41. 41.
    Zhang F, Zheng M. Dosimetric evaluation of conventional RT, 3-D conformal RT and direct machine parameter optimisation intensity-modulated RT for breast cancer after conservative surgery. J Med Imaging Radiat Oncol. 2011;55:595–602.CrossRefGoogle Scholar
  42. 42.
    Jin GH, Chen LX, Deng XW, Liu XW, Huang Y, Huang XB. A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different RT techniques: conventional tangential field, filed-in-filed, tangential-IMRT, multi-beam IMRT and VMAT. Radiat Oncol. 2013;8:89.CrossRefGoogle Scholar
  43. 43.
    Liu H, Chen X, He Z, Li J. Evaluation of 3D-CRT, IMRT and VMAT RT plans for left breast cancer based on clinical dosimetric study. Comput Med Imaging Graph. 2016;54:1–5.CrossRefGoogle Scholar
  44. 44.
    Popescu CC, Olivotto IA, Beckham WA, Ansbacher W, Zavgorondni S, Shaffer R, et al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity modulated RT for locoregional RT of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys. 2010;76:287–95.CrossRefGoogle Scholar
  45. 45.
    Chen MH, Chuang ML, Bornstein BA, Gelman R, Harris J, Manning WJ. Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals. Circulation. 1997;96:3269–72.CrossRefGoogle Scholar
  46. 46.
    Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, Bornstein B. Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys. 2000;47:895–904.CrossRefGoogle Scholar
  47. 47.
    Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys. 2001;49:199–204.CrossRefGoogle Scholar
  48. 48.
    Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol. 2013;106:28–32.CrossRefGoogle Scholar
  49. 49.
    Lymberis SC, DeWyngaert JK, Parhar P, Chhabra AM, Fenton-Kerimian M, Chang J, et al. Prospective assessment of optimal individual position (prone versus supine) for breast RT: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys. 2012;84:902–9.CrossRefGoogle Scholar
  50. 50.
    Kirby AM, Evans PM, Donovan EM, Convery HM, Haviland JS, Yarnold JR. Prone versus supine positioning for whole and partial-breast RT: a comparison of non-target tissue dosimetry. Radiother Oncol. 2010;96:178–84.CrossRefGoogle Scholar
  51. 51.
    Mulliez T, Speleers B, Madani I, et al. Whole breast RT in prone and supine position: is there a place for multi-beam IMRT? Radiat Oncol. 2013;8:151.CrossRefGoogle Scholar
  52. 52.
    Weed DW, Edmundson GK, Vicini FA, Chen PY, Martinez AA. Accelerated partial breast irradiation: a dosimetric comparison of three different techniques. Brachytherapy. 2005;4:121–9.CrossRefGoogle Scholar
  53. 53.
    Patel RR, Becker SJ, Das RK, Mackie TR. A dosimetric comparison of accelerated partial breast irradiation techniques: multicatheter interstitial brachytherapy, three dimensional conformal RT, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;68:935–42.CrossRefGoogle Scholar
  54. 54.
    Fogliata A, Bolsi A, Cozzi L. Critical appraisal of treatment techniques based on conventional photon beams, intensity modulated photon beams and proton beams for therapy of intact breast. Radiother Oncol. 2002;62:137–45.CrossRefGoogle Scholar
  55. 55.
    U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02603341. RADCOMP. Accessed 18th Aug 2018.
  56. 56.
    Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70.CrossRefGoogle Scholar
  57. 57.
    Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM, Prime II Investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomized controlled trial. Lancet. 2015;16:266–73.CrossRefGoogle Scholar
  58. 58.
    Gagliardi G, Constine LS, Mioseenko V, Correa C, Pierce LJ, Allen AM, Marks LB. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76S:S77–85.CrossRefGoogle Scholar
  59. 59.
    Cancer Trials Support Unit. https://www.ctsu.org/Public/Default.aspx. NSABP B-51. Accessed 29 May 2018.
  60. 60.
    Cancer Trials Support Unit. https://www.ctsu.org/Public/Default.aspx. Alliance A011202. Accessed 29 May 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Lifespan Cancer InstituteRhode Island Hospital, Warren Alpert Medical School of Brown UniversityProvidenceUSA
  2. 2.Department of Radiation Oncology, Tufts Medical CenterTufts University School of MedicineBostonUSA

Personalised recommendations